HB6660, titled the Replace Animal Tests Act of 2025, would require federal agencies to rely on scientifically satisfactory non-animal test methods whenever those methods are available and accepted for regulatory use. The bill applies to data submitted to covered agencies, defined as the Consumer Product Safety Commission, the Department of Agriculture, the Environmental Protection Agency, and the Food and Drug Administration. In general, it would make it unlawful to submit animal-test-derived data when an accepted non-animal method can satisfy the information requirement, or when an agency has already granted a waiver from the animal-testing requirement.
The bill includes several exceptions. It would not affect animal-test data generated before enactment, data generated overseas to satisfy foreign regulatory requirements, or animal data requested by a covered agency when no practicably available non-animal method existed at the time of testing. It also allows agencies to request specified animal tests in writing if they provide a clear justification that available non-animal methods are not appropriate for the product or substance at issue. When animal testing is still necessary, the bill directs regulated entities to minimize the number of animals used and reduce pain, suffering, distress, or lasting harm.
HB6660 would also give agencies enforcement and implementation tools. Covered agencies could refuse to accept data generated in violation of the act and could impose civil penalties of up to $10,000 per violation. Within one year of enactment, each covered agency would have to issue guidance on acceptable non-animal methods and, where appropriate, revise regulations to eliminate corresponding animal-test-data requirements. The bill also requires annual public progress reports on non-animal testing use, animal numbers and species used, waivers issued, and the purposes of animal and non-animal testing, with personally identifiable and proprietary information removed before publication.
The bill’s likely impact would be to accelerate the federal transition toward alternative testing methods in product safety, environmental, agricultural, and drug regulation. It would affect regulated companies, research entities, and the four covered agencies by changing what kinds of test data can be submitted and accepted, while also increasing reporting and transparency obligations. The measure would not ban all animal testing, but it would substantially limit when animal-derived data can be used for regulatory compliance.
There is no recorded committee debate or vote history in the provided materials, so sentiment cannot be measured from floor or committee action. Based on the bill text alone, the measure appears strongly pro–animal welfare and pro-alternative testing, with a regulatory modernization focus. Potential points of contention likely center on whether non-animal methods are sufficiently validated for all products, how much discretion agencies should have to require animal data, and whether the civil penalties and reporting requirements could create compliance burdens for industry and agencies.
The bill would amend federal regulatory practice by prohibiting submission of animal-test-derived data to the CPSC, USDA, EPA, and FDA when an accepted non-animal method is available or a waiver has been issued, subject to specified exceptions. It would require agencies to issue guidance, potentially revise regulations to remove animal-data requirements, impose civil penalties for violations, and publish annual reports on testing practices and waivers. The practical effect would be to shift regulatory testing toward validated alternatives and away from live-animal methods.
No committee transcripts or votes were provided, so there is no recorded legislative sentiment to summarize. On its face, the bill is framed as a reform to reduce animal testing and promote scientifically accepted alternatives, suggesting support from animal welfare and alternative-methods advocates. Any opposition would likely come from stakeholders concerned about scientific adequacy, regulatory flexibility, or implementation costs.
The main likely points of contention are the scope of agency discretion, the definition and acceptance of “scientifically satisfactory” non-animal methods, and whether agencies should be able to require animal data in limited circumstances. Industry and some regulators may object to the civil penalties, reporting mandates, and potential delays if alternative methods are not yet available for certain substances or products. Animal welfare advocates, by contrast, would likely support the bill’s restrictions and minimization requirements, while still watching for broad exceptions that could preserve animal testing in practice.